Journal
OBSTETRICS AND GYNECOLOGY
Volume 124, Issue 2, Pages 481-483Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AOG.0000000000000371
Keywords
-
Categories
Ask authors/readers for more resources
BACKGROUND: Primary immune thrombocytopenia is not a rare event during pregnancy, and it must be carefully managed to avoid hemorrhagic complications for the mother. After failure of first-line treatments, the teratogenicity and toxicity of other therapeutic agents limit the available options and treatment. CASES: We describe the cases of two pregnant patients with corticosteroid-refractory immune thrombocytopenia who were successfully treated by romiplostim, a thrombopoietin receptor agonist, without any fetal or maternal complications. CONCLUSION: Romiplostim may represent an important alternative treatment choice during pregnancy for immune thrombocytopenia cases refractory to first-line therapy, especially because of its speed of action and high efficacy. Nevertheless, further data are required to provide definitive evidence of its safety for newborns.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available